Bispecific antibodies (PD-1/CTLA-4) vs. PD-1 inhibitors with platinum-based chemotherapy±bevacizumab as first-line therapy for persistent, recurrent, or metastatic cervical cancer: a retrospective matched cohort study.

Cancer Immunol Immunother · 2025 · PMC12552208 · PMID 41136631

Europe PMC DOI

hedged sentence

0.0790

closest p · 1.6× alpha

0.0790

boldest claim

The sentences

did not reach statistical significancep = 0.079so close (0.05 < p ≤ 0.1)

Although this trend did not reach statistical significance ( p = 0.079), it has been a consistent empirical observation in our clinical practice.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.